Physician profile
Chad A Shields
NPI 1881974129
$821.58
in general payments reported to CMS, 2019-2025
11 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.00 · 2022: $222 · 2023: $306 · 2024: $127 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.51 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $132.28 | 2022-2023 | Nuzyra |
| Lilly USA, LLC | $42.65 | 2023 | Mounjaro, Trulicity |
| Axsome Therapeutics, INC. | $40.50 | 2024-2025 | Auvelity |
| Amgen INC. | $36.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.76 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Siemens Medical Solutions USA, INC. | $23.99 | 2023 | Mammomat Revelation |
| Glaxosmithkline, LLC. | $17.42 | 2022 | |
| Smith+Nephew, INC. | $17.34 | 2022 | |
| Abiomed | $15.76 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.